Sigyn Therapeutics (SIGY, $4.12) was a top loser over the last three months, falling to $4.12 per share. A.I.dvisor analyzed 850 stocks in the Biotechnology Industry for the 3-month period ending February 14, 2025, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.